Health and Healthcare
Johnson & Johnson Takes on $14 Billion Tax Charge With Q4 Earnings
Published:
Last Updated:
Johnson & Johnson (NYSE: JNJ) reported its fourth-quarter financial results before the markets opened on Tuesday. The company said that it had $1.74 in earnings per share (EPS) and $20.2 billion in revenue, compared with consensus estimates from Thomson Reuters that called for $1.72 in EPS and $20.07 billion in revenue. The same period from last year had $1.58 in EPS and $18.11 billion in revenue.
During the quarter, the company incurred a one-time charge associated with the tax legislation of $13.6 billion.
For the fourth quarter, operational sales results increased 9.4% and the positive impact of currency was 2.1%. Domestic sales increased 9.8%. International sales increased 13.5%, reflecting operational growth of 9.0% and a positive currency impact of 4.5%.
The company reported its segment results for the quarter as follows:
- Consumer sales totaled $1.38 billion.
- Pharmaceutical sales totaled $5.78 billion.
- Medical Devices sales totaled $3.31 billion.
- U.S. sales totaled $10.47 billion.
Alex Gorsky, board chair and chief executive, commented:
Johnson & Johnson delivered strong adjusted earnings per share growth of 8.5% and total shareholder return of greater than 24% in 2017, driven by the robust performance of our Pharmaceutical business, while continuing to make investments in acquisitions, innovation and strategic partnerships to accelerate growth in each of our businesses. As we enter 2018 and look beyond, we are experiencing an incredible pace of change in health care. Johnson & Johnson is uniquely positioned to lead during this dynamic era and deliver innovative solutions for patients and consumers that drive sustainable, long-term growth. We are pleased with the passage of recent legislation modernizing the U.S. tax system, which enables Johnson & Johnson to invest in innovation at higher levels to help address the most challenging unmet medical needs facing health care today.
Shares closed Monday at $148.14, with a consensus analyst price target of $148.50 and a 52-week trading range of $110.76 to $148.32. Following the announcement, the stock was up almost 1% at $149.35 in early trading indications Tuesday.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
